Alphamab Oncology (HKG: 9966), a China-based biopharmaceutical company, has announced the presentation of the latest results from the Phase I/II study of its investigational drug JSKN033 at the 2024 Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024). The study focuses on patients with HER2-expressing advanced or metastatic solid tumors.
Study Design and Results
The open, multi-center, first-in-human Phase I/II study aims to evaluate the safety, tolerability, and preliminary efficacy of JSKN033 in patients with advanced HER2-expressing solid tumors (IHC ≥ 1+) or HER2 mutant non-small cell lung cancer (NSCLC). The results indicated that JSKN033 exhibited good safety and showed preliminary encouraging anti-tumor activity in solid tumor patients who had experienced disease progression after multiple lines of treatment.
JSKN033’s Unique Formulation
JSKN033 is described as the world’s first subcutaneous co-formulation, consisting of the HER2 bispecific antibody JSKN003 and the PD-L1 monoclonal antibody envafolimab, which is also the world’s first subcutaneous anti-PD-L1 inhibitor. Envafolimab received marketing approval in China in November 2021, marking a significant milestone for the treatment of certain cancers.-Fineline Info & Tech
Leave a Reply